Partway through study implementation, allocation to methadone maintenance therapy was changed from randomization to participant choice; randomization to HHRP-M continued throughout.
A total of 26 patients therapy was changed secondary to SECG monitoring which represented 14.6% of high-risk patients and 1.1% of low-risk patients.
Therapy was changed because of toxicity and drug-resistance by hCG criteria in 11 (21%) and 10 (19%) patients, respectively.
The indinavir free-base suspension was less bioavailable than the dry-filled capsule formulation, and therapy was changed to capsules in all children.
However, she additionally developed left hydronephrosis and multiple bone metastases in the skull, right acetabulum, and right iliac crest 5 months after the therapy was changed (Fig. 1e).
Antibiotic therapy was changed to tobramycin 0.3%% eye drops hourly right eye 2 days post-presentation to improve compliance but was again unsuccessful due to irritation from tobramycin.
One year and 8 months after the operation, she developed right hydronephrosis and swollen para-aortic lymph nodes and her hormone therapy was changed to fulvestrant therapy.
Antibiotic therapy was changed to intravenous meropenem.
Antifungal therapy was changed to posaconazole.
The antimicrobial drug therapy was changed to oxacillin and ofloxacin.
Antimicrobial drug therapy was changed to atovaquone and azithromycin.
